Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube Mar 11, 2026
Company Deals Drug

AstraZeneca Initiates CLARITY-Gastric 02 Phase III – Sonesitatug Vedotin Combo Triggers $45 Million Milestone from KYM Biosciences

Fineline Cube Mar 11, 2026
Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Fineline Cube Mar 11, 2026
Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Fineline Cube Mar 11, 2026
Company Drug

JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial

Fineline Cube Apr 11, 2023

China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...

Company Deals Digital

Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China

Fineline Cube Apr 11, 2023

China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma...

Company

CStone Pharmaceuticals Reduces Ayvakit Price to Boost Accessibility in China

Fineline Cube Apr 11, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced a lower recommended price for its precision medicine...

Company Deals

Hangzhou Baikai Biomedical and Leads Biolabs Partner to Develop Innovative ADCs

Fineline Cube Apr 11, 2023

China-based Hangzhou Baikai Biomedical Co., Ltd and Leads Biolabs Inc. have announced a partnership aimed...

Hospital Policy / Regulatory

NHC Report: Performance Assessment of National Class 2 Public Hospitals in 2021

Fineline Cube Apr 11, 2023

The National Health Commission (NHC) has released the “Report on the National Monitoring and Analysis...

Company Deals

Cuban-Chinese Biotechnology Center Showcases Drug and Vaccine Progress to Cuban Delegation

Fineline Cube Apr 11, 2023

Researchers from Cuba and China at the Yongzhou joint biotechnology innovation center in China’s Hunan...

Medical Device Policy / Regulatory

Hebei Leads Sanming Alliance in Launching 8th VBP for 19 Medical Consumables

Fineline Cube Apr 11, 2023

The Hebei medical drug and device centralized procurement center has announced the start of the...

Company Drug

Takeda Pharma’s Iclusig Poised for Priority Review by CDE for Leukemia Treatments

Fineline Cube Apr 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Takeda Pharma’s (TYO: 4502) Iclusig...

Company Deals

Arctic Vision Partners with Sinopharm Group for Ophthalmic Product Distribution in China

Fineline Cube Apr 11, 2023

China-based ophthalmology specialist Arctic Vision has entered into a strategic partnership with Sinopharm Group Distribution...

Drug Policy / Regulatory

FDA Issues Complete Response Letters to Six Novel Drugs in Q1 2023

Fineline Cube Apr 10, 2023

According to an analysis, the US FDA issued complete response letters (CRLs) to six novel...

Company Deals

Bioyond Robotics Secures $29 Million in Series A and A+ Financing Rounds

Fineline Cube Apr 10, 2023

Bioyond Robotics, a Shanghai-based intelligent automation company, has reportedly raised around RMB 200 million (USD...

Policy / Regulatory

Henan Province Sees 53.6% Price Reduction in Neuro and Peripheral Intervention Consumables Tender

Fineline Cube Apr 10, 2023

The Henan Province Public Resources Trading Center has released a notification regarding the completion of...

Company Deals

Jiangsu Hillgene Biopharma Secures Tens of Millions in Series A Financing for Cell Therapy R&D

Fineline Cube Apr 10, 2023

China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has...

Company

Forecyte Bio Expands with New Cell and Gene Therapy GMP Facility in Shanghai

Fineline Cube Apr 10, 2023

Maryland-based Contract Development and Manufacturing Organization (CDMO) Forecyte Biotechnologies has announced the opening of a...

Company Drug

Yiling Pharmaceutical’s XY0206 Advances to Phase III Trial for FLT3-ITD AML

Fineline Cube Apr 10, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced its plans to initiate a Phase...

Company Medical Device

Jiangsu Yuyue Medical Secures NMPA Approval for Semi-Automatic External Defibrillator

Fineline Cube Apr 10, 2023

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223), a China-based medical device company,...

Company Drug

MicuRx Pharmaceuticals Initiates Phase III Study for MRX-4 in Diabetic Foot Infection Treatment

Fineline Cube Apr 10, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study...

Company Deals

AstraZeneca Partners with Guangzhou Institute to Advance Respiratory Medicine Research

Fineline Cube Apr 10, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced a partnership with China’s Guangzhou Institute...

Company Policy / Regulatory

Indonesia and China Deepen Healthcare Ties with High-Level Dialogue and New Agreements

Fineline Cube Apr 10, 2023

Indonesia’s deputy minister of health, Dante Saksono Harbuwono, visited China last week as part of...

Policy / Regulatory

Shanxi Province Begins Historical Procurement Data Collection for Pacemaker VBP Round

Fineline Cube Apr 10, 2023

In preparation for a volume-based procurement (VBP) round, Shanxi province has initiated the gathering of...

Posts pagination

1 … 506 507 508 … 633

Recent updates

  • Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029
  • J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer
  • Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia
  • Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up
  • Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription – NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Company Drug

Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.